期刊
EBIOMEDICINE
卷 59, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ebiom.2020.102944
关键词
alpha-Synuclein; Antisense oligonucleotide; Axonal neurodegeneration; Dopamine neurotransmission; Mouse and monkey models; Parkinson's disease
资金
- Ministry of Economy and Competitiveness (MINECO) [SAF2016-75797-R, RTC-2014-2812-1, RTC-2015-3309-1]
- European Regional Development Fund (ERDF), UE [SAF2016-75797-R, RTC-2014-2812-1, RTC-2015-3309-1]
- Therapeutic Pipeline Program Spring 2014 Program, The Michael J. Fox Foundation [9238]
- Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM)
- Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED)
Background: Progressive neuronal death in monoaminergic nuclei and widespread accumulation of alpha-synuclein are neuropathological hallmarks of Parkinson's disease (PD). Given that alpha-synuclein may be an early mediator of the pathological cascade that ultimately leads to neurodegeneration, decreased alpha-synuclein synthesis will abate neurotoxicity if delivered to the key affected neurons. Methods: We used a non-viral gene therapy based on a new indatraline-conjugated antisense oligonucleotide (IND-ASO) to disrupt the alpha-synuclein mRNA transcription selectively in monoamine neurons of a PD-like mouse model and elderly nonhuman primates. Molecular, cell biology, histological, neurochemical and behavioral assays were performed. Findings: Intracerebroventricular and intranasal IND-ASO administration for four weeks in a mouse model with AAV-mediated wild-type human alpha-synuclein overexpression in dopamine neurons prevented the synthesis and accumulation of alpha-synuclein in the connected brain regions, improving dopamine neurotransmission. Likewise, the four-week IND-ASO treatment led to decreased levels of endogenous alpha-synuclein protein in the midbrain monoamine nuclei of nonhuman primates, which are affected early in PD. Conclusions:: The inhibition of alpha-synuclein production in dopamine neurons and its accumulation in cortical/ striatal projection areas may alleviate the early deficits of dopamine function, showing the high translational value of antisense oligonucleotides as a disease modifying therapy for PD and related synucleinopathies. (C) 2020 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据